Shanghai Ark Biopharmaceutical Co., Ltd.

This phase 3 trial is testing whether an experimental drug called AK3280 can slow the decline in lung function for people with idiopathic pulmonary fibrosis (IPF), a condition that causes progressive lung scarring. About 263 adults aged 40 and older with IPF will receive either A…

This early-stage study is the first time AK0406 is being tested in humans. It will involve 32 healthy adults to check if the drug is safe and how the body processes it. No treatment is being given for any disease—this is purely a safety check.